Mevalonates, Ras and Breast Cancer
Abstract
Therapy of any cancer is designed to control growth of cancer cells while permitting the function and proliferation of normal cells. 6-fluoromevalonate (Fmev) can inhibit proliferation of leukemic cells lines while not affecting normal lymphocytes. This selective inhibition appears to be a consequence of expression of oncogenic Ras. Here we are evaluating the ability of Fmev to selectively interfere with proliferation of breast cancer cells. We have shown that Fmev can inhibit the proliferation of normal breast epithelial cells. However the proliferation of, some, but not all, transformed breast epithelial cell lines expressing oncogenic Ras is inhibited by concentrations of Fmev that do not affect normal breast epithelia. Our study of the contribution of oncogenic Ras to this sensitization, suggests that it is an indirect mechanism involving reduced adherence to substrate. In addition, while growth of RAS transformed cells on plastic is inhibited by Fmev, growth in suspension is not. Our results do not support pursuing Fmev as an effective therapy against Ras transformed breast epithelia.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2001
- Accession Number
- ADA405165
Entities
People
- Michael A. White
Organizations
- University of Texas at Dallas